Matti Lehtinen - Concepedia

Author

Matti Lehtinen

Also Known As

A R Kreimer, J LEHTINEN, J Lehtinen, J. LEHTINEN, J. Lehtinen, Jorma Lehtinen, Jorma Paavonen, Lehtinen M, Lehtinen, Matti, M Lehtinen

484

Publications

23.2K

Citations

H-Index

160

Concepts

All Affiliations

Tampere University University of Helsinki Karolinska Institutet Finnish Cancer Registry

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	94	11.5K
2	Public Health	33	52	5.5K
3	Natural Sciences	2	2	74
4	Health Sciences	1	1	30
5	Allergy	1	1	62

Matti Lehtinen

215

Publications

20.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Jorma Paavonen, Paulo Naud, Jorge Salmerón, The Lancet As04-adjuvanted VaccineGynecologyOncogenic Hpv TypesCancer-associated VirusCervical Cancer Prevention	2009	1.6K
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, The Lancet Oncology VaccinationVaccinologyVaccine DevelopmentCervical CancerHuman Papillomavirus Vaccines	2005	1.6K
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Jorma Paavonen, David Jenkins, F. Xavier Bosch, The Lancet VaccinationVaccine SafetyInterim AnalysisPreventive MedicinePhase Iii Double-blind	2007	1.3K
Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck Jon Mork, A. Kathrine Lie, Eystein Glattre, New England Journal of Medicine	2001	942
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, British Journal of Cancer	2006	804
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler, The Lancet Oncology VaccinationCervical Cancer ScreeningHpv-16/18 As04-adjuvanted VaccineCervical CancerCervical Health	2011	693
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland, The Lancet Oncology VaccinationVaccine SafetyCervical Cancer ScreeningPreventive MedicineCervical Cancer	2011	499
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 Luisa L. Villa, Kevin A. Ault, Anna R. Giuliano, Vaccine VaccinationVaccine DevelopmentHuman Papillomavirus VaccinesVaccine TargetImmunology	2006	465
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine Sven‐Eric Olsson, Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Vaccine VaccinationVaccine DevelopmentL1 Virus-like ParticleHuman Papillomavirus VaccinesImmune Memory	2007	454
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries Pentti Tuohimaa, Leena Tenkanen, Merja Ahonen, International Journal of Cancer	2003	430

Page 1